Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Panel Says Covis’ Makena Should Be Withdrawn – And This Time It Wasn’t Close

19 Oct 2022

• By Sue Sutter

Makena thumbs down — • Source: Shutterstock

Related Content

Makena Withdrawal Dilemma: Advisory Cmte. Split Offers No Clear Direction For US FDA

30 Oct 2019

Makena: New Randomized Trial May Only Happen If Drug Stays On The US Market

19 Oct 2022

FDA’s Peter Stein And Lessons From Makena: There Are Limits To Regulatory Flexibility

19 Oct 2022

The Makena Deciders: FDA Commissioner Califf, Chief Scientist Bumpus To Jointly Make Final Call On Drug’s Fate

11 Oct 2022

Makena Hearing Panel Is Deep With Maternal-Fetal Medicine Experience, As Preferred By Covis

14 Oct 2022

Related Companies

Merck & Co., Inc.

Additional Topics

United States Review Pathway Post Market Regulation & Studies Advisory Committees Regulation Gynecology & Urology BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.